Acer Therapeutics Announces Promotion of Tanya Hayden to Chief Operating Officer
21 juin 2022 08h32 HE
|
Acer Therapeutics Inc.
NEWTON, Mass., June 21, 2022 (GLOBE NEWSWIRE) -- Acer Therapeutics Inc. (Nasdaq: ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for...
Acer Therapeutics Issues Statement Regarding PDUFA Target Action Date for ACER-001
07 juin 2022 08h30 HE
|
Acer Therapeutics Inc.
NEWTON, Mass., June 07, 2022 (GLOBE NEWSWIRE) -- Acer Therapeutics Inc. (Nasdaq: ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for...
Acer Therapeutics Reports Q1 2022 Financial Results and Provides Corporate Update
16 mai 2022 16h01 HE
|
Acer Therapeutics Inc.
NEWTON, Mass., May 16, 2022 (GLOBE NEWSWIRE) -- Acer Therapeutics Inc. (Nasdaq: ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for...
Acer Therapeutics Announces Agreement with FDA on Special Protocol Assessment for its Phase 3 EDSIVO™ (celiprolol) Trial in Vascular Ehlers-Danlos Syndrome Patients
09 mai 2022 08h30 HE
|
Acer Therapeutics Inc.
NEWTON, Mass., May 09, 2022 (GLOBE NEWSWIRE) -- Acer Therapeutics Inc. (Nasdaq: ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious...
Acer Therapeutics and Relief Therapeutics Announce Presentation of ACER-001 Data at the Genetic Metabolic Dieticians International Conference
06 mai 2022 08h30 HE
|
Acer Therapeutics Inc.
NEWTON, Mass. and GENEVA, May 06, 2022 (GLOBE NEWSWIRE) -- Acer Therapeutics Inc. (Nasdaq: ACER) (“Acer”) and its collaboration partner, Relief Therapeutics Holding SA (SIX: RLF, OTCQB: RLFTF,...
Acer Therapeutics to Participate in H.C. Wainwright Global Investment Conference
05 mai 2022 08h30 HE
|
Acer Therapeutics Inc.
NEWTON, Mass., May 05, 2022 (GLOBE NEWSWIRE) -- Acer Therapeutics Inc. (Nasdaq: ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious...
Acer Therapeutics and Relief Therapeutics Announce Presentation of ACER-001 Data at the Society for Inherited Metabolic Disorders Annual Meeting
12 avr. 2022 08h30 HE
|
Acer Therapeutics Inc.
NEWTON, Mass. and GENEVA, April 12, 2022 (GLOBE NEWSWIRE) -- Acer Therapeutics Inc. (Nasdaq: ACER) (“Acer”) and its collaboration partner, Relief Therapeutics Holding SA (SIX: RLF, OTCQB: RLFTF,...
Acer Therapeutics’ EDSIVO™ (celiprolol) Granted FDA Breakthrough Therapy Designation for Vascular Ehlers-Danlos Syndrome
04 avr. 2022 08h30 HE
|
Acer Therapeutics Inc.
NEWTON, Mass., April 04, 2022 (GLOBE NEWSWIRE) -- Acer Therapeutics Inc. (Nasdaq: ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for...
Acer Therapeutics Regains Compliance with Nasdaq Listing Standard
31 mars 2022 08h30 HE
|
Acer Therapeutics Inc.
NEWTON, Mass., March 31, 2022 (GLOBE NEWSWIRE) -- Acer Therapeutics Inc. (Nasdaq: ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for...